Free Trial

Calumet (CLMT) to Release Earnings on Friday

Calumet logo with Energy background

Key Points

  • Calumet (CLMT) is set to release its Q2 2025 earnings on August 8th, with expectations of a loss of ($0.42) per share and revenue of $982.88 million.
  • The company reported a previous quarterly EPS of ($1.03), missing estimates by ($0.62), while revenue was down 1.2% year over year.
  • Calumet stock has seen recent insider activity with significant sales, including 100,000 shares sold by Director Jennifer Straumins at an average price of $13.17.
  • Looking to export and analyze Calumet data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Calumet (NASDAQ:CLMT - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $982.88 million for the quarter.

Calumet (NASDAQ:CLMT - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The oil and gas company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.62). The business had revenue of $993.90 million for the quarter, compared to analysts' expectations of $899.62 million. During the same quarter in the prior year, the company earned ($0.51) EPS. Calumet's quarterly revenue was down 1.2% on a year-over-year basis. On average, analysts expect Calumet to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Calumet Stock Down 1.2%

CLMT traded down $0.18 during trading on Monday, reaching $15.33. 94,748 shares of the company's stock were exchanged, compared to its average volume of 1,232,889. Calumet has a fifty-two week low of $7.68 and a fifty-two week high of $25.29. The business has a 50 day moving average price of $15.60 and a 200 day moving average price of $14.05. The company has a market capitalization of $1.32 billion, a P/E ratio of -3.83 and a beta of 0.91.

Analysts Set New Price Targets

A number of research firms have weighed in on CLMT. The Goldman Sachs Group decreased their price target on shares of Calumet from $16.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Bank of America began coverage on shares of Calumet in a research note on Tuesday, May 13th. They set a "buy" rating and a $15.00 price target on the stock. Finally, Wells Fargo & Company decreased their price target on shares of Calumet from $23.00 to $21.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Calumet presently has a consensus rating of "Hold" and a consensus target price of $18.50.

Get Our Latest Report on Calumet

Insider Activity

In related news, SVP Gregory J. Morical sold 25,123 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $16.69, for a total transaction of $419,302.87. Following the transaction, the senior vice president owned 39,415 shares in the company, valued at $657,836.35. This represents a 38.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jennifer Straumins sold 100,000 shares of the company's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $13.17, for a total transaction of $1,317,000.00. Following the transaction, the director owned 1,084,589 shares in the company, valued at approximately $14,284,037.13. This trade represents a 8.44% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 275,123 shares of company stock worth $4,113,303. 4.07% of the stock is owned by corporate insiders.

About Calumet

(Get Free Report)

Calumet, Inc engages in the manufacturing, formulating, and marketing of a diversified slate of specialty branded products and renewable fuels to customers across a broad range of consumer-facing and industrial markets. It operates through the following segments: Specialty Products & Solutions, Performance Brands, Montana/Renewables, and Corporate.

See Also

Earnings History for Calumet (NASDAQ:CLMT)

Should You Invest $1,000 in Calumet Right Now?

Before you consider Calumet, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Calumet wasn't on the list.

While Calumet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines